Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020;

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                     to

Commission file number 001-38161

 

 

Calyxt, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Delaware

 

27-1967997

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

 

2800 Mount Ridge Road

 

 

Roseville, MN

 

55113-1127

(Address of principal executive offices)

 

(Zip Code)

(651) 683-2807

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered or to be registered pursuant to Section 12(b) of the Act.

 

 

 

 

 

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange on which

registered

 

 

 

Common Stock (0.0001 par value)

  

CLXT

  

The NASDAQ Global Market

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

 

 

 

 

 

 

 

Large accelerated filer

  

  

Accelerated filer

  

Non-accelerated filer

  

  

Smaller reporting company

  

 

  

 

  

Emerging growth company

  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of May 6, 2020, there were 33,040,520 shares of common stock, $0.0001 par value per share, outstanding.

 

 


Table of Contents

 

 

 

 

 

 

 

 

PART I. FINANCIAL INFORMATION

 

4

 

 

 

 

 

Item 1. Consolidated Financial Statements

 

4

 

 

 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

15

 

 

 

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

23

 

 

 

 

 

Item 4. Controls and Procedures

 

24

 

 

 

 

 

PART II. OTHER INFORMATION

 

24

 

 

 

 

 

Item 1. Legal Proceedings

 

24

 

 

 

 

 

Item 1A. Risk Factors

 

24

 

 

 

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

25

 

 

 

 

 

Item 6. Exhibits

 

26

 

 

 

 

 

SIGNATURE

 

27

 

 

 

 

 


Table of Contents

Terms

When we use the terms “we,” “us,” the “Company,” or “our” in this report, unless the context otherwise requires, we are referring to Calyxt, Inc. When we use the term “Cellectis,” we are referring to Cellectis S.A., our majority stockholder. Cellectis is a clinical-stage biotechnological company, employing its core proprietary technologies to develop best-in-class products in the field of immune-oncology.

We own the names and trademarks for Calyxt® and Calyno®; we also own or license other trademarks, trade names and service marks of Calyxt appearing in this Quarterly Report on Form 10-Q. The name and trademark Cellectis® and TALEN®, and other trademarks, trade names and service marks of Cellectis appearing in this Quarterly Report are the property of Cellectis. This Quarterly Report also contains additional trade names, trademarks and service marks belonging to other companies. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). We may also make forward-looking statements in other reports filed with the Securities and Exchange Commission, in materials delivered to stockholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements.

We have made these forward-looking statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” or  the negative of these terms and other similar terminology. Forward-looking statements in this report include statements about the potential impact of the COVID-19 pandemic on our business and operating results, our future financial performance, product pipeline and development, commercialization efforts and sales of commercial products, regulatory progression, potential collaborations and partnerships and their contribution to our financial results, cash usage, growth strategies and anticipated trends in our business. These and other forward-looking statements are predictions and projections about future events and trends based on our current expectations, objectives and intentions and premised on current assumptions. Our actual results, level of activity, performance or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; the impact of increased competition; disruptions at our key facilities; changes in customer preferences and market acceptance of our products; competition for collaboration partners and the successful execution of collaborations; the impact of adverse events during development, including unsuccessful field trials or disruptions in seed production; failures by third-party contractors; inaccurate demand forecasting; disruptions to supply chains, including transportation and storage functions; commodity price conditions; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; management changes; dislocations in the capital markets; and other important factors discussed under the caption entitled “Risk Factors” in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 5, 2020 (our Annual Report) and our subsequent reports on Forms 10-Q (including under the caption entitled “Risk Factors” in Part II, Item 1A of this Quarterly Report) and 8-K.

Any forward-looking statement made by us are based only on information currently available to us when, and speaks only as of the date, such statement is made. Except as required by securities and other applicable laws, we do not assume any obligation to update or revise any forward-looking statement as a result of new information, future developments or otherwise.

 

- 2 -


Table of Contents

Market Data

Unless otherwise indicated, information contained in this Quarterly Report concerning our industry and the markets in which we operate is based on information from various sources, including independent industry publications. In presenting this information, we have also made assumptions based on such data and other similar sources, and on our knowledge of, and our experience to date in, the potential markets for our product. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section entitled “Risk Factors” in our Annual Report and other subsequent reports on Forms 10-Q and 8-K filed with the SEC. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

Website Disclosure

We use our website (www.calyxt.com), our corporate Twitter account (@Calyxt_Inc) and our corporate LinkedIn account (https://www.linkedin.com/company/calyxt-inc) as routine channels of distribution of company information, including press releases, analyst presentations, and supplemental financial information, as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor our website and our corporate Twitter and LinkedIn accounts in addition to following press releases, filings with the SEC and public conference calls and webcasts.

Additionally, we provide notifications of announcements as part of our website. Investors and others can receive notifications of new press releases posted on our website by signing up for email alerts.

None of the information provided on our website, in our press releases or public conference calls and webcasts or through social media is incorporated into, or deemed to be a part of, this Quarterly Report or in any other report or document we file with the SEC, and any references to our website or our corporate Twitter and LinkedIn accounts are intended to be inactive textual references only.

- 2 -


Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CALYXT, INC.

CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Par Value and Share Amounts)

 

 

March 31, 2020 (unaudited)

 

December 31,

2019

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

$

7,385

 

$

58,610

 

Short-term investments

 

38,620

 

 

 

Restricted cash

 

388

 

 

388

 

Accounts receivable

 

841

 

 

1,122

 

Due from related parties

 

7

 

 

 

Inventory

 

3,198

 

 

2,594

 

Prepaid expenses and other current assets

 

1,594

 

 

808

 

Total current assets

 

52,033

 

 

63,522

 

Non-current restricted cash

 

1,045

 

 

1,040

 

Land, buildings, and equipment

 

22,902

 

 

23,212

 

Other non-current assets

 

441

 

 

324

 

Total assets

$

76,421

 

$

88,098

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

$

1,085

 

$

1,077

 

Accrued expenses

 

2,093

 

 

2,544

 

Accrued compensation

 

1,363

 

 

2,181

 

Due to related parties

 

554

 

 

977

 

Current portion of financing lease obligations

 

361

 

 

356

 

Other current liabilities

 

94

 

 

61

 

Total current liabilities

 

5,550

 

 

7,196

 

Financing lease obligations

 

18,194

 

 

18,244

 

Other non-current liabilities

 

141

 

 

150

 

Total liabilities

 

23,885

 

 

25,590

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.0001 par value; 275,000,000 shares authorized; 33,090,799 shares issued and 32,990,647 shares outstanding as of March 31, 2020, and 33,033,689 shares issued and 32,951,329 shares outstanding as of December 31, 2019

 

3

 

 

3

 

Additional paid-in capital

 

186,859

 

 

185,588

 

Common stock in treasury, at cost; 100,152 shares as of March 31, 2020, and 82,360 shares as of December 31, 2019

 

(1,043

)

 

(1,043

)

Accumulated deficit

 

(133,120

)

 

(122,057

)

Accumulated other comprehensive income (loss)

 

(163

)

 

17

 

Total stockholders’ equity

 

52,536

 

 

62,508

 

Total liabilities and stockholders’ equity

$

76,421

 

$

88,098

 

 

See accompanying notes to these consolidated financial statements.

- 3 -


Table of Contents

CALYXT, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited and in Thousands Except Shares and Per Share Amounts)

 

 

Three Months Ended March 31,

 

 

2020

 

 

2019

 

Revenue

$

2,377

 

 

$

157

 

Cost of goods sold

 

3,884

 

 

 

34

 

Gross margin

 

(1,507

)

 

 

123

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

2,787

 

 

 

2,219

 

Selling and supply chain

 

1,580

 

 

 

904

 

General and administrative

 

4,720

 

 

 

4,162

 

Management fees

 

62

 

 

 

361

 

Total operating expenses

 

9,149

 

 

 

7,646

 

Loss from operations

 

(10,656

)

 

 

(7,523

)

Interest, net

 

(398

)

 

 

172

 

Foreign currency transaction loss

 

(9

)

 

 

(24

)

Loss before income taxes

 

(11,063

)

 

 

(7,375

)

Income taxes

 

 

 

 

 

Net loss

$

(11,063

)

 

$

(7,375

)

Basic and diluted loss per share

$

(0.34

)

 

$

(0.23

)

Weighted average shares outstanding - basic and diluted

 

32,988,141

 

 

 

32,677,944

 

See accompanying notes to these consolidated financial statements.

- 4 -


Table of Contents

CALYXT, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited and in Thousands Except Shares Outstanding)

 

Three months ended

March 31, 2020

 

Shares

Outstanding

 

 

Common

Stock

 

 

Additional

Paid-In

Capital

 

 

Shares

in

Treasury

 

 

Accumulated

Deficit

 

 

Accumulated

Other

Comprehensive

Income (Loss)

 

 

Total

Stockholders’

Equity

 

Balance at December 31, 2019

 

 

32,951,329

 

 

$

3

 

 

$

185,588

 

 

$

(1,043

)

 

$

(122,057

)

 

$

17

 

 

$

62,508

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11,063

)

 

 

 

 

 

(11,063

)

Stock based compensation

 

 

57,110

 

 

 

 

 

 

1,271

 

 

 

 

 

 

 

 

 

 

 

 

1,271

 

Shares withheld for net share settlement

 

 

(17,792

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(180

)

 

 

(180

)

Balance at March 31, 2020

 

 

32,990,647

 

 

$

3

 

 

$

186,859

 

 

$

(1,043

)

 

$

(133,120

)

 

$

(163

)

 

$

52,536

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

March 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances at December 31, 2018

 

 

32,648,893

 

 

$

3

 

 

$

176,069

 

 

$

(230

)

 

$

(82,445

)

 

$

 

 

$

93,397

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(7,375

)

 

 

 

 

 

(7,375

)

Stock based compensation

 

 

43,296

 

 

 

 

 

 

1,556

 

 

 

 

 

 

 

 

 

 

 

 

1,556

 

Issuance of common stock

 

 

 

 

 

 

 

 

125

 

 

 

 

 

 

 

 

 

 

 

 

125

 

Balances at March 31, 2019

 

 

32,692,189

 

 

$

3

 

 

$

177,750

 

 

$

(230

)

 

$

(89,820

)

 

$

 

 

$

87,703

 

See accompanying notes to these consolidated financial statements.

- 5 -


Table of Contents

CALYXT, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited and in Thousands)

 

 

Three Months Ended March 31,

 

 

2020

 

 

2019

 

Operating activities

 

 

 

 

 

 

 

Net loss

$

(11,063

)

 

$

(7,375

)

Adjustments to reconcile net loss to net cash used by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

452

 

 

 

342

 

Stock-based compensation

 

1,271

 

 

 

1,556

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable

 

281

 

 

 

(124

)

Due to/from related parties

 

(430

)

 

 

(1,114

)

Inventory

 

(604

)

 

 

(379

)

Prepaid expenses and other current assets

 

(786

)

 

 

(629

)

Accounts payable

 

8

 

 

 

(94

)

Accrued expenses

 

(451

)

 

 

(397

)

Accrued compensation

 

(818

)

 

 

(418

)

Other current liabilities

 

(156

)

 

 

(428

)

Other non-current assets

 

(120

)

 

 

(216

)

Net cash used by operating activities

 

(12,416

)

 

 

(9,276

)

Investing activities

 

 

 

 

 

 

 

Short-term investments

 

(38,620

)

 

 

 

Purchases of land, buildings, and equipment

 

(139

)

 

 

(346

)

Net cash used by investing activities

 

(38,759

)

 

 

(346

)

Financing activities

 

 

 

 

 

 

 

Repayments of financing lease obligations

 

(45

)

 

 

(59

)

Proceeds from the exercise of stock options

 

 

 

 

125

 

Net cash (used) provided by financing activities

 

(45

)

 

 

66

 

Net decrease in cash, cash equivalents and restricted cash

 

(51,220

)

 

 

(9,556

)

Cash, cash equivalents and restricted cash - beginning of period

 

60,038

 

 

 

95,288

 

Cash, cash equivalents and restricted cash - end of period

$

8,818

 

 

$

85,732

 

 

See accompanying notes to these consolidated financial statements.

- 6 -


Table of Contents

 

CALYXT, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. BASIS OF PRESENTATION & SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Our unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP or GAAP) for interim financial information and with the rules and regulations of the Securities and Exchange Commission (SEC) applicable to interim financial statements. In our opinion, the accompanying consolidated financial statements reflect all adjustments necessary for a fair presentation of our statements of financial position, results of operations and cash flows for the periods presented but they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Except as otherwise disclosed herein, these adjustments consist of normal recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole or any other interim period.

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from these estimates.

Certain prior year amounts have been reclassified to conform to the current year presentation.

For further information, refer to the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 5, 2020. The accompanying Balance Sheet as of December 31, 2019 was derived from the audited consolidated financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and notes included in the Annual Report on Form 10-K for the year ended December 31, 2019.

Short-term investments

We consider investments with more than ninety days to maturity at issuance to be short-term investments. These short-term investments are considered trading securities and are carried at fair value with any unrealized gains and losses recorded in current earnings as a component of interest, net.

2. FINANCIAL INSTRUMENTS, FAIR VALUE, HEDGING ACTIVITIES, AND CONCENTRATIONS OF CREDIT RISK

The carrying values of cash and cash equivalents, restricted cash, due from related parties, accounts payable, due to related parties and all other current liabilities approximate fair value.

We measure certain assets and liabilities at fair value on a recurring basis, including short-term investments, financing lease obligations and commodity futures and options. The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the measurement date as follows:

Level 1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and liabilities.

Level 2: Fair values are based on observable quoted prices other than those in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

- 7 -


Table of Contents

Level 3: Fair values are based on at least one significant unobservable input for the asset or liability.

Fair Value Measurements and Financial Statement Presentation

The fair values of our assets, liabilities, and derivative positions recorded at fair value and their respective levels in the fair value hierarchy as of March 31, 2020 and December 31, 2019, were as follows:

 

 

March 31, 2020

 

 

March 31, 2020

 

 

Fair Values of Assets

 

 

Fair Values of Liabilities

 

In Thousands

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Other items reported at fair value:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments

$

38,620

 

 

$

 

 

$

 

 

$

38,620

 

 

$

 

 

$

 

 

$

 

 

$

 

Commodity futures and options

 

603

 

 

 

 

 

 

 

 

 

603

 

 

 

 

 

 

 

 

 

 

 

 

 

Financing lease obligations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

15,509

 

 

 

 

 

 

15,509

 

Total

$

39,223

 

 

$

 

 

$

 

 

$

39,223

 

 

$

 

 

$

15,509

 

 

$

 

 

$

15,509

 

 

 

December 31, 2019

 

 

December 31, 2019

 

 

Fair Values of Assets

 

 

Fair Values of Liabilities

 

In Thousands

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Other items reported at fair value:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financing lease obligations

$

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

15,651

 

 

$

 

 

$

15,651

 

Commodity futures and options

 

62

 

 

 

 

 

 

 

 

 

62

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

$

62

 

 

$

 

 

$

 

 

$

62

 

 

$

 

 

$

15,651

 

 

$

 

 

$

15,651

 

The composition of our short-term investments at March 31, 2020 and December 31, 2019 were as follows:

 

As of March 31,

 

 

As of December 31,

 

In Thousands

2020

 

 

2019

 

Corporate debt securities

$

29,677

 

 

$

 

Commercial paper

 

8,943

 

 

 

 

Total

$

38,620

 

 

$

 

 

Commodity Price Risk

We enter into seed and grain production agreements (Forward Purchase Contracts) with settlement values based on commodity futures market prices. These Forward Purchase Contracts allow the counterparty to fix their sales prices at various times as defined in the contract. We are also engaged in the business of selling soybean oil and meal under a variety of pricing structures. We may enter hedging arrangements to either fix variable exposures or convert fixed prices to floating prices through commodity derivative contracts. As of March 31, 2020, we held commodity contracts with a notional amount of $23.6 million.

We have designated all our commodity derivative contracts as cash flow hedges. As a result, all gains or losses associated with recording commodity derivative contracts at fair value are recorded as a component of accumulated other comprehensive income (loss) (AOCI). We reclassify amounts from AOCI to cost of goods sold when we sell the underlying products to which those hedges relate. As of March 31, 2020, we expect the entire AOCI balance to be reclassified into earnings within the next eight months.

Certain amounts related to our hedging activities are as follows:

 

 

Amount of Gain (Loss)

Recognized in AOCI

 

 

Amount of Gain (Loss)

Reclassified to Earnings

 

 

For the Three Months Ended March 31,

 

 

For the Three Months Ended March 31,

 

In thousands

2020

 

 

2019

 

 

2020

 

 

2019

 

Cash flow hedges:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commodity derivative contracts

$

(163

)

 

$

 

 

$

14

 

 

$

 

Total

$

(163

)

 

$

 

 

$

14

 

 

$

 

 

- 8 -


Table of Contents

Foreign Exchange Risk

Foreign currency fluctuations affect our foreign currency cash flows related primarily to payments to Cellectis. Our principal foreign currency exposure is to the euro. We do not hedge these exposures, and we do not believe that the current level of foreign currency risk is significant to our operations.

Concentrations of Credit Risk

We invest our cash, cash equivalents and restricted cash in highly liquid securities and investment funds and until late December 2019, also held deposits at a financial institution that exceeded insured limits. In the first quarter of 2020, we diversified this risk by shifting our investments to a diverse portfolio of short-dated, high investment-grade securities we classify as short-term investments that are recorded at fair value in our consolidated financial statements. We ensure the credit risk in this portfolio is in accordance with our internal policies and if necessary, make changes to investments to ensure credit risk is minimized. We have not experienced any counterparty credit losses.

3. RELATED-PARTY TRANSACTIONS

We have several agreements that govern our relationship with Cellectis, some of which require us to make payments to Cellectis. Pursuant to our management services agreement with Cellectis, we incurred management fee expenses of $62,000 for the three months ended March 31, 2020, and $361,000 for the three months ended March 31, 2019.

Cellectis has also guaranteed the lease agreement for our headquarters. Cellectis’ guarantee of our obligations under the lease will terminate at the end of the second consecutive calendar year in which our tangible net worth exceeds $300 million.

TALEN® is our primary gene-editing technology, and it is the foundation of our technology platform. TALEN® technology was invented by researchers at the University of Minnesota and Iowa State University and exclusively licensed to Cellectis. We obtained an exclusive license for the TALEN® technology for commercial use in plants from Cellectis. We also license other technology from Cellectis. We owe Cellectis royalties on any revenue we generate from sales of products less certain amounts as defined in the license agreement, as well as a percentage of any sublicense revenues. We have incurred $33,000 of license and royalty fees owed to Cellectis for the three months ended March 31, 2020, and $25,000 for the three months ended March 31, 2019.

We have entered into various agreements with the University of Minnesota, pursuant to which we have been granted both exclusive and non-exclusive license agreements that carry annual license fees, milestone payments, royalties, and associated legal fees. These agreements primarily relate to gene-editing tools, enabling technologies and germplasm. We have incurred $12,000 of costs pursuant to these agreements for the three months ended March 31, 2020, and $4,000 for the three months ended March 31, 2019.

4. NET LOSS PER SHARE

Basic and diluted loss per share was calculated using the following:

 

 

For the Three Months Ended March 31,

 

In Thousands, Except Share Data and Per Share Amounts

2020

 

 

2019

 

Net loss

$

(11,063

)

 

$

(7,375

)

Weighted average shares outstanding - basic and diluted

 

32,988,141

 

 

 

32,677,944

 

Basic and diluted loss per share

$

(0.34

)

 

$

(0.23

)

 

 

As of March 31,

 

 

2020

 

 

2019

 

Anti-dilutive stock options, restricted stock units, and performance stock units

 

5,328,268

 

 

 

4,385,595

 

All outstanding stock options and restricted stock units are excluded from the calculation since they are anti-dilutive.

We have not used the treasury method in determining the number of anti-dilutive stock options and restricted stock units in the table above.

- 9 -


Table of Contents

5. STOCK-BASED COMPENSATION

We use broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management’s interests are aligned with those of our shareholders. We have also granted equity-based awards to directors, nonemployees, and certain employees of Cellectis.

In December 2014, we adopted the Calyxt, Inc. Equity Incentive Plan (2014 Plan), which allowed for the grant of stock options, and in June 2017, we adopted the 2017 Omnibus Plan (2017 Plan), which allowed for the grant of stock options, performance shares and other types of equity awards.

As of March 31, 2020, 1,976,394 shares were registered and available for grant under effective registration statements, while 2,770,295 shares were available for grant in the form of stock options, restricted stock, restricted stock units, and performance stock units under the 2017 Plan. Stock-based awards currently outstanding also include awards granted under the 2014 Plan, under which no further awards can be granted.

Stock Options

The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows:

 

 

Three Months Ended March 31,

 

 

2020

 

 

2019

 

Estimated fair values of stock options granted

$

5.19

 

 

$

9.45

 

Assumptions:

 

 

 

 

 

 

 

Risk-free interest rate

 

1.7

%

 

 

2.5

%

Expected volatility

 

77.4

%

 

 

78.9

%

Expected term (in years)

 

6.9

 

 

 

6.9

 

 

We estimate the fair value of each option on the grant date or other measurement dates if applicable using a Black-Scholes option-pricing model, which requires us to make predictive assumptions regarding future stock price volatility, employee exercise behavior and dividend yield. The risk-free interest rate for periods during the expected term of the options is based on the United States Treasury zero-coupon yield curve in effect at the date of grant. We estimate our future stock price volatility using the historical volatility of comparable public companies over the expected term of the option. Our expected term represents the period that options granted are expected to be outstanding determined using the simplified method. We have not paid dividends on our common stock and we do not currently plan to pay any cash dividends in the foreseeable future.

Option strike prices are set at 100 percent or more of the closing share price on the date of grant, and generally vest over six years following the grant date. Options generally expire 10 years after the date of grant.

Information on stock option activity is as follows:

 

Options

Exercisable

 

 

Weighted-

Average

Exercise

Price Per

Share

 

 

Options

Outstanding

 

 

Weighted-

Average

Exercise

Price Per

Share

 

Balance as of December 31, 2019

 

1,789,567

 

 

$

8.73

 

 

 

4,481,359

 

 

$

11.73

 

Granted

 

 

 

 

 

 

 

 

 

60,000

 

 

 

7.30

 

Forfeited or expired

 

 

 

 

 

 

 

 

 

(235,894

)

 

 

15.61

 

Balance as of March 30, 2020

 

1,890,357

 

 

$

8.97

 

 

 

4,305,465

 

 

$

11.46

 

 

Stock-based compensation expense related to stock option awards is as follows:

 

 

 

Three Months Ended March 31,

 

In Thousands

 

2020

 

 

2019

 

Stock-based compensation expense

 

$

1,006

 

 

$

768

 

 

At March 31, 2020, options outstanding and exercisable had no aggregate intrinsic value and the weighted average remaining contractual term was 6.6 years.

- 10 -


Table of Contents

Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows:

 

Three Months Ended March 31,

 

In Thousands

2020

 

 

2019

 

Net cash proceeds

$

 

 

$

125

 

Intrinsic value of options exercised

$

 

 

$

353

 

 

As of March 31, 2020, unrecognized compensation expense related to non-vested stock options was $10.6 million. This expense will be recognized over 56 months on average.

Restricted Stock Units

Units settled in stock subject to a restricted period may be granted under the 2017 Plan. Restricted stock units generally vest and become unrestricted over five years after the date of grant.

Information on restricted stock unit activity is as follows:

 

Number of

Restricted Stock

Units Outstanding

 

 

Weighted-

Average Grant

Date Fair Value

 

Unvested balance at December 31, 2019

 

813,526

 

 

$

10.31

 

Vested

 

(51,973

)

 

 

9.80

 

Forfeited

 

(50,417

)

 

 

10.45

 

Unvested balance at March 31, 2020

 

711,136

 

 

$

10.33

 

 

The total grant-date fair value of restricted stock unit awards that vested is as follows:

 

 

Three Months Ended March 31,

 

In Thousands

 

2020

 

 

2019

 

Grant-date fair value

 

$

510

 

 

$

133

 

 

Stock-based compensation expense related to restricted stock units is as follows:

 

 

Three Months Ended March 31,

 

In Thousands

 

2020

 

 

2019

 

Stock-based compensation expense

 

$

155

 

 

$

787

 

 

We treat stock-based compensation awards granted to employees of Cellectis as deemed dividends. We recorded deemed dividends as follows:

 

 

Three Months Ended March 31,

 

In Thousands

 

2020

 

 

2019

 

Deemed dividends from grants to Cellectis employees

 

$

224

 

 

$

411

 

 

As of March 31, 2020, unrecognized compensation expense related to restricted stock units was $2.5 million. This expense will be recognized over 43 months on average.

Performance Stock Units

In June 2019, we granted 311,667 performance stock units under the 2017 Plan to three executive officers. The performance stock units will vest at 50%, 100% or 120% of the shares under the award at the end of a three-year performance period based upon increases in the value of our common stock from the grant price of $12.48. The performance stock units will be settled in restricted stock upon vesting, with restrictions on transfer lapsing on the second anniversary of the restricted stock issuance date.

Stock-based compensation expense related to performance stock units is as follows:

 

 

Three Months Ended March 31,

 

In Thousands

 

2020

 

 

2019

 

Stock-based compensation expense

 

$

110

 

 

$

 

 

- 11 -


Table of Contents

As of March 31, 2020, unrecognized compensation expense related to performance stock units was $1.9 million. This expense will be recognized over 51 months on average.

6. INCOME TAXES

We provide for a valuation allowance when it is more likely than not that we will not realize a portion of the deferred tax assets. We have established a full valuation allowance for deferred tax assets due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, we have not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements.

As of March 31, 2020, there were no material changes to what we disclosed regarding tax uncertainties or penalties as of December 31, 2019.

7. LEASES, OTHER COMMITMENTS, AND CONTINGENCIES

Litigation and Claims

We are not currently a party to any material pending legal proceeding.

Leases

We lease our headquarters facility, office equipment, and other items. Our headquarters lease involved the sale of land and improvements to a third party who then constructed the facility. This lease is considered a financing lease.

We also have an equipment financing arrangement that is considered a financing lease. This arrangement has a term of four years for each draw. We were required to deposit cash into a restricted account in an amount equal to the future rent payments required by the lease. As of March 31, 2020, this restricted cash totaled $1.4 million. We have the option to request the return of excess collateral annually in December.

Rent expense from operating leases was as follows:

 

 

 

Three Months Ended March 31,

 

In Thousands

 

2020

 

 

2019

 

Rent expense from operating leases

 

$

24

 

 

$

49

 

 

Other Commitments

As of March 31, 2020, we have noncancelable commitments to purchase grain from farmers and seed from growers at dates throughout 2020 aggregating $9.2 million based on current commodity futures market prices, other payments to growers, and estimated yields per acre. This amount is not recorded in the consolidated financial statements because we have not taken delivery of the grain as of March 31, 2020. If growers do not plant our soybeans, we allow the grain production contacts to be cancelled. Therefore, we do not include commitments to purchase grain as noncancelable commitment until the corresponding seed is planted.

8. EMPLOYEE BENEFIT PLAN

We provide a 401(k) defined contribution plan for all regular full-time employees who have completed three months of service. We match employee contributions up to certain amounts and those matching contributions vest immediately.

 

 

 

Three Months Ended March 31,

 

In Thousands

 

2020

 

 

2019

 

Employee benefit plan expenses

 

$

120

 

 

$

56

 

 

- 12 -


Table of Contents

9. SUPPLEMENTAL INFORMATION

Certain balance sheet amounts are as follows:

 

 

As of March 31,

 

 

As of December 31,

 

In Thousands

2020

 

 

2019

 

Inventory:

 

 

 

 

 

 

 

Raw materials

$

2,535

 

 

$

2,211

 

Work-in-process

 

445

 

 

 

272

 

Finished goods

 

218

 

 

 

111

 

Total

$

3,198

 

 

$

2,594

 

 

Certain statements of operations amounts are as follows:

 

 

Three Months Ended March 31,

 

In Thousands

2020

 

 

2019

 

Stock compensation expense:

 

 

 

 

 

 

 

Research and development

$

319

 

 

$

241

 

Selling and supply chain

 

(251

)

 

 

63

 

General and administrative

 

1,203

 

 

 

1,286

 

Total

$

1,271

 

 

$

1,590

 

 

 

Three Months Ended March 31,

 

In Thousands

2020

 

 

2019

 

Interest, net:

 

 

 

 

 

 

 

Interest expense

$

(372

)

 

$

(370

)

Interest income

 

(26

)

 

 

542

 

Total

$

(398

)

 

$

172

 

 

 

 

 

 

 

 

 

 

Certain statements of cash flows amounts are as follows:

 

 

As of March 31, 2020

 

In Thousands

2020

 

 

2019

 

Cash, cash equivalents, restricted cash, and short-term investments:

 

 

 

 

 

 

 

Cash and cash equivalents

$

7,385

 

 

$

84,231

 

Restricted cash

 

1,433

 

 

 

1,501

 

Total cash, cash equivalents, and restricted cash:

 

8,818

 

 

 

85,732

 

Short-term investments

 

38,620

 

 

 

 

Total cash, cash equivalents, restricted cash, and short-term investments:

$

47,438

 

 

$

85,732

 

 

 

Three Months Ended March 31,

 

In Thousands

2020

 

 

2019

 

Supplemental cash flow information:

 

 

 

 

 

 

 

Interest paid

$

367

 

 

$

365

 

 

10. SEGMENT INFORMATION

We operate in a single reportable segment, agricultural products. Our current commercial focus is North America. Our major product categories are high oleic soybean oil and high oleic soybean meal.

11. SUBSEQUENT EVENTS

On April 19, 2020, we received a $1,517,500 loan under the Paycheck Protection Program implemented under the Coronavirus Aid, Relief and Economic Security (CARES) Act. The loan has a term of two years, an interest rate of one percent with no interest payable for six months and is forgivable if certain employee and compensation levels are maintained and the proceeds are used for qualifying purposes. After the initial six-month deferral period, the loan requires monthly payments of principal and interest until maturity with respect to any portion of the Paycheck Protection Program loan that is not forgiven.

- 13 -


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and related notes, which are included elsewhere in this Quarterly Report on Form 10-Q.

EXECUTIVE OVERVIEW

We are a technology company focused on delivering plant-based solutions that are healthy and sustainable. We intend to bring these products to market one of two ways. First, through an integrated business model where we leverage third party assets in the agricultural supply chain to process grains and sell the resulting products. Second, through collaboration arrangements or license agreements with third parties. In a collaboration arrangement, we expect to jointly develop products and to receive payments for the use of our innovations, upon the achievement of development milestones, and from royalties upon commercial sale of products. We also have an option to monetize our technology platform by strategically licensing our innovations to others. We expect to use the integrated business model in soybeans and wheat and collaborate or license in all other crops. We may also choose to collaborate in wheat and soybeans to increase margins and reduce our need for working capital. We are currently exploring product opportunities in alfalfa, canola, hemp, oats, peanuts, peas, potato, soybeans, wheat, and other crops. As of March 31, 2020, there were 18 projects at the Discovery stage or later in our development across alfalfa, canola, hemp, oats, potatoes, soybeans, and wheat.

Early in the second quarter, we advanced our first hemp project to the commercialization phase of development. This project, which did not use gene editing, leveraged our plant breeding expertise to quickly purify and stabilize key varieties of a partner’s germplasm.  We expect to launch the product in the near term. While not expected to be significant to revenue, this successful project enabled the gathering of valuable insights and data that will benefit the development of other hemp projects which are expected to launch beginning in 2023.

We are an early-stage company and have incurred net losses since our inception. As of March 31, 2020, we had an accumulated deficit of $133.1 million. Our net losses were $11.1 million for the three months ended March 31, 2020.

We expect to continue to incur significant expenses and operating losses for the next several years. Those expenses and losses may fluctuate significantly from quarter-to-quarter and year-to-year. We expect that our expenses will be driven by:

continuing to advance the R&D of our current and future products;

conducting additional breeding and field trials of our current and future products;

seeking regulatory and marketing approvals for our products;

acquiring or in-licensing other products, technologies, germplasm, or other biological material;

maintaining, protecting, expanding, and defending our intellectual property portfolio;

making royalty and other payments under any in-license agreements;

seeking to attract and retain new and existing skilled personnel;

securing manufacturing arrangements for commercial production;

building out additional sales, marketing, and distribution capabilities, including relationships across our supply chain, to commercialize products that have completed the development process;

investing in our infrastructure to support the scale-up of the business;

addressing the impacts of the ongoing novel coronavirus (“COVID-19”) pandemic, including implementing our expense reduction efforts and modified crush strategy and seeking to bolster our liquidity position in light of changing business needs and uncertain macro-economic conditions; and

experiencing any delays or encountering issues with any of the above, including due to COVID-19 and its impacts.

OUR RELATIONSHIP WITH CELLECTIS AND COMPARABILITY OF OUR RESULTS

We are a majority-owned subsidiary of Cellectis. As of March 31, 2020, Cellectis owned 68.8% of our outstanding common stock.

Our historical financial information reflects expense allocations for certain support functions that were provided on a centralized basis pursuant to a management services agreement. As a result, such historical financial information may not reflect the financial condition, results of operations or cash flows we would have achieved as a stand-alone company and not a subsidiary of Cellectis during such historical periods. Effective with the end of the third quarter of 2019 we have internalized nearly all the services Cellectis previously provided. Cellectis has also guaranteed the lease of our headquarters facility.

Cellectis has certain contractual rights as well as rights pursuant to our certificate of incorporation and bylaws, in each case, as long as it maintains threshold beneficial ownership levels in our shares.

- 14 -


Table of Contents

We hold an exclusive license from Cellectis that broadly covers the use of engineered nucleases for plant gene editing. This intellectual property covers methods to edit plant genes using “chimeric restriction endonucleases,” which include TALEN®, CRISPR/Cas9, zinc finger nucleases, and some types of meganucleases.

FINANCIAL OPERATIONS OVERVIEW

Revenue

For the three months ended March 31, 2020, we recognized revenue from the sales of high oleic soybean oil and meal. We do not recognize revenue from seed transactions because of the grower’s commitment to sell their crop to us. We benefit from the cash upon payment and defer the net profit on the seed to inventory and recognize that benefit when the grower delivers grain to us. We are also exploring additional revenue-generating opportunities including collaborations, licensing, R&D activities, and other value capture models for our technology platform.

Cost of Goods Sold and Inventory

Prior to 2019, our cost of goods sold represented immaterial costs associated with our out-licensing activities. Costs we incurred associated with the purchasing, storing, transporting and processing grain, net of proceeds of seed sales (Grain Costs), were expensed as R&D. Beginning during the first quarter of 2019, we began to capitalize all Grain Costs into inventory. This affects the year-over-year comparability of costs of goods sold, gross margins and R&D expenses. For the three months ended March 31, 2019, Grain Costs expensed as R&D totaled $149,000.

Cost of goods sold also includes crush and refining losses that are expensed as incurred since they do not add to the value of the finished products. All other grain and risk management costs, net of the benefit from our seed activity, are capitalized to inventory and relieved to cost of goods sold as the high oleic soybean oil and meal is sold. Any valuation adjustments to inventory are recognized as incurred.

Research and Development Expense

Research and development (R&D) expenses consist of the costs of performing activities to discover and develop products and advance our intellectual property. We recognize R&D expenses as they are incurred.

Excluding the Grain Costs mentioned above, our R&D expenses consist primarily of employee-related costs for our R&D personnel, fees for contractors who support product development and breeding activities, expenses for trait validation, purchasing material and supplies for our laboratories, licensing, facilities, regulatory, and other costs associated with owning and operating our own laboratories. R&D expenses also include costs to write and support the research for filing patents.

Selling and Supply Chain Expense

Selling and Supply Chain (S&SC) expenses consist primarily of employee-related expenses for selling our products, acreage acquisition, managing the supply chain and business development, as well as costs to market our products and an allocation of facility and information technology expenses.

General and Administrative Expense

General and administrative (G&A) expenses consist primarily of employee-related expenses for our executive, legal, intellectual property, information technology, finance, and human resources functions. Other G&A expenses include facility and information technology expenses not otherwise allocated to R&D or S&SC expenses, professional fees for auditing, tax and legal services, expenses associated with maintaining patents, consulting costs and other costs of our information systems.

Interest, net

Interest, net is comprised of interest income resulting from investments of cash and cash equivalents and short-term investments, any unrealized gains and losses on short-term investments, and interest expense on our financing lease obligations. It is also driven by balances, yields, and timing of financing activities.

Recent Developments – COVID-19

As a company operating within the food supply chain, our operations in Minnesota are classified as critical sector work under the State of Minnesota “stay at home” executive order adopted in response to the COVID-19 pandemic, which became effective on March 27, 2020. While most of our laboratory workers remain onsite at our headquarters, we transitioned all other employees to remote work arrangements. In accordance with the Minnesota executive order and CDC and WHO guidelines, we also have implemented health and safety measures for the protection of our onsite workers.

- 15 -


Table of Contents

Despite the remote work arrangements for many of our employees, we have continued much of our operations in R&D and in seed distribution and sale. As of the date of this report, our R&D programs and seed distribution activities have not experienced any material delays.

Our seed production takes place primarily in the United States and its territories with contra season production also occurring in Argentina. Third party warehousing for seed storage and our limited number of processing partners (e.g., storage, transportation, crushers and refiners) are located in the Upper Midwest region of the United States. Our operations team has been working with our seed production, warehousing and processing partners and with our logistics partners to manage and mitigate the impact of supply chain disruptions. To date, supply chain disruptions have not had a material impact on our operations. However, additional or enhanced COVID-19 related closures, or increased disruptions from existing COVID-19 related preventive measures, could further disrupt our supply chains, particularly with respect to transportation across borders or outside the Upper Midwest.

We currently target sales of our high oleic soybean oil to foodservice, food manufacturing, animal nutrition, and industrial market segments. The COVID-19 pandemic has had a significant adverse impact on the food industry, which has substantially reduced food industry demand for vegetable oils. Accordingly, beginning in the last weeks of the first quarter 2020 and continuing into the second quarter 2020, we have experienced lower demand for our high oleic soybean oil, corresponding to the overall lowering of demand for all vegetable oils. In addition, excess supply of vegetable oil has driven lower prices, and we believe our high oleic soybean oil may be particularly impacted by lower pricing within the premium oil category. Looking forward, we expect prices for premium oil to remain low and demand for vegetable oil to remain depressed, into the second half of 2020 and possibly beyond.

We currently target sales of our high oleic soybean meal to dairy, poultry, and pork producers. On April 28, 2020, President Trump signed an executive order directing the Department of Agriculture to ensure meat and poultry processors in the U.S. continue operations uninterrupted to the maximum extent possible. Nevertheless, the COVID-19 pandemic has impacted protein processing facilities, with several processing facilities temporarily closing or suspending operations, which is impacting the upstream operations in the industry. The COVID-19 impact on protein supply is likely to have a corresponding impact on the demand for our high oleic soybean meal. Looking forward, we expect prices for soybean meal to remain low and, depending on herd sizes, soybean meal demand may also be depressed, into the second half of 2020 and possibly beyond.

In response to changing demand, pricing pressure and uncertainty among our customers and target customers caused by the COVID-19 pandemic, we have adjusted our short-term crush strategy and have canceled crushes scheduled for late May, June and July 2020. This change avoids storage costs for oil and is expected to shift product sales efforts into the second half of 2020, when potentially customer demand may partially recover depending on the timing and extent of resumption of normal operating activities among our customers. We are also accelerating the purchase of the remaining 2019 grain crop, which was originally expected to be purchased before August 31, 2020, enabling us to take advantage of the lower prices currently available and reduce our ultimate cash outlay for that grain.

Until we can generate substantial cash flow, we expect to finance a portion of future cash needs through public or private equity or debt financings, government or other third-party funding, various payments we may receive from future collaborators in product development and commercialization activities, and licensing arrangements. Our financing needs are subject to change depending on, among other things, the success of our product development efforts, our revenue and our efforts to effectively manage expenses. The effects of the COVID-19 pandemic on the financial markets and broader economic uncertainties, may make obtaining capital through equity or debt financings more challenging and have exacerbated the risk that such capital, if available, may not be available on terms acceptable to us.

In response to current economic conditions, we have taken and expect to take in the future actions to increase our financial flexibility and liquidity. We have commenced a review of operating expenses and have postponed non-essential capital expenditures. Additionally, on April 19, 2020, we received a $1,517,500 loan under the Payroll Protection Program under the CARES Act, which will be applied during this period of economic uncertainty to payroll and other qualifying fixed costs. As a result of these actions and our anticipated reductions in cash expenditures, we expect our monthly cash usage to decrease beginning April 2020 and decrease overall for the balance of 2020 as compared to 2019 and our previous expectations. With these actions, we expect our current cash runway to now extend to late 2021. We continue to evaluate additional strategies to further reduce our cash usage.

We will also continue to evaluate our operations and adjust based on the safety of our employees, demand signals, the health of our supply chain and distribution network, and government mandates and local orders.

- 16 -


Table of Contents

Our actual results, level of activity, performance or achievements could be materially different from those anticipated in the forward-looking statements included in this discussion of the COVID-19 pandemic and its impacts as a result of certain factors, including, but not limited to, those discussed under the caption “Risk Factors” in our Annual Report and our subsequent reports on Forms 10-Q (including under the caption entitled “Risk Factors” in this Quarterly Report) and 8-K.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2020 COMPARED TO THE THREE MONTHS ENDED MARCH 31, 2019

A summary of our results of operations for the three months ended March 31, 2020 and 2019 follows:

 

 

Three Months Ended March 31,

 

 

2020